Efungumab

none 762260-74-2Y DB16151Y none BM86P708HW D09711 Efungumab(trade nameMycograb) was adrugdeveloped by NeuTec Pharma (a subsidiary ofNovartis), intended to treatcandidemia(a bloodstream infection caused by pathogenicyeast) in combination withamphotericin B. TheEuropean Medicines Agencyhas twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues. Chemically, efungumab is asingle-chain variable fragmentof ahumanmonoclonal antibody.As such, it "grabs" onto fungal hsp90, hence its proposed trade name. Its ability to potentiate the effects of the antifungal amphotericin B in culture were later found to be non-specific.